Century Therapeutics, Inc. (IPSC)
NASDAQ:IPSC
Want to see IPSC full AI Analyst Report?
Top Page
Century Therapeutics
(NASDAQ:IPSC)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.00
▼(-23.08% Downside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by weak financial performance (ongoing losses and cash burn) and limited support from valuation (negative P/E). These are partially offset by a relatively solid balance sheet, neutral technical signals, and positive pipeline/financing-related corporate updates—though with meaningful dilution risk.
Positive Factors
Allogeneic iPSC platform
Century’s iPSC-derived allogeneic NK and T-cell approach establishes an off-the-shelf manufacturing model that can scale across multiple indications. Structurally, this reduces per-patient manufacturing complexity versus autologous therapies and enables platform reuse, supporting long-term commercial potential if clinical efficacy is proven.
Negative Factors
Persistent cash burn
Operating and free cash flow have been negative across most reported periods and in the TTM, indicating persistent cash burn. This structural cash consumption forces reliance on external funding or partnerships to sustain development, limiting strategic flexibility and increasing the likelihood of dilutive or costly financing until commercial revenues emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic iPSC platform
Century’s iPSC-derived allogeneic NK and T-cell approach establishes an off-the-shelf manufacturing model that can scale across multiple indications. Structurally, this reduces per-patient manufacturing complexity versus autologous therapies and enables platform reuse, supporting long-term commercial potential if clinical efficacy is proven.
Read all positive factors
Century Therapeutics (IPSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$405.80M
Dividend YieldN/A
Average Volume (3M)848.02K
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth-100.00%
EPS Growth-290.26%
CountryUS
Employees140
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.25
Shares Outstanding180,354,810
10 Day Avg. Volume975,589
30 Day Avg. Volume848,025
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.86
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$5.67Price Target Upside117.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Century Therapeutics Business Overview & Revenue Model
Company Description
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogene...
How the Company Makes Money
Century Therapeutics’ revenue generation to date has been primarily tied to collaboration and partnership-related income rather than recurring commercial product sales (as a clinical-stage company). Key ways it makes money include: (1) Collaborati...
Century Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 109.16M | 6.59M | 2.23M | 5.20M | 0.00 |
| Gross Profit | -29.86M | 96.06M | 6.59M | 2.23M | 5.20M | -4.58M |
| EBITDA | -89.90M | 3.45M | -111.47M | -121.21M | -121.20M | -89.92M |
| Net Income | -107.78M | -9.58M | -126.57M | -136.67M | -130.93M | -95.82M |
Balance Sheet | ||||||
| Total Assets | 326.55M | 223.70M | 353.22M | 360.69M | 486.54M | 437.38M |
| Cash, Cash Equivalents and Short-Term Investments | 134.80M | 117.11M | 189.29M | 172.74M | 315.50M | 222.88M |
| Total Debt | 48.02M | 43.56M | 53.83M | 48.17M | 49.41M | 25.12M |
| Total Liabilities | 61.81M | 64.77M | 191.85M | 175.94M | 183.81M | 41.14M |
| Stockholders Equity | 264.74M | 158.94M | 161.36M | 184.75M | 302.74M | 396.24M |
Cash Flow | ||||||
| Free Cash Flow | -95.91M | -104.72M | -110.29M | -102.08M | -16.55M | -133.97M |
| Operating Cash Flow | -94.50M | -103.88M | -110.14M | -88.35M | 14.05M | -89.00M |
| Investing Cash Flow | -33.04M | 107.50M | 47.48M | 61.13M | -13.13M | -298.34M |
| Financing Cash Flow | 126.68M | 173.00K | 74.56M | -9.72M | 27.16M | 417.77M |
Century Therapeutics Technical Analysis
Positive
2.60
Price Trends
2.28
Negative
2.24
Positive
1.48
Positive
Market Momentum
-0.03
Positive
50.56
Neutral
47.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 2.6 is above the 20-day moving average (MA) of 2.23, above the 50-day MA of 2.28, and above the 200-day MA of 1.48, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 50.56 is Neutral, neither overbought nor oversold. The STOCH value of 47.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.
Century Therapeutics Risk Analysis
Century Therapeutics disclosed 90 risk factors in its most recent earnings report. Century Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Century Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $43.86M | -2.74 | -0.97% | ― | ― | 21.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $405.80M | -1.81 | -53.23% | ― | -100.00% | -290.26% | |
47 Neutral | $35.20M | -0.18 | 75.79% | ― | -63.28% | 54.23% | |
45 Neutral | $13.70M | -0.67 | -526.36% | ― | ― | 16.33% | |
43 Neutral | $31.69M | -1.34 | -218.67% | ― | ― | 48.96% | |
42 Neutral | $18.66M | -0.32 | -309.60% | ― | ― | 65.65% |
* Healthcare Sector Average
IPSC
Century Therapeutics
2.25
1.67
285.93%
TPST
Tempest Therapeutics
1.26
-5.64
-81.74%
ATNM
Actinium Pharmaceuticals
1.01
-0.52
-33.99%
BTAI
Bioxcel Therapeutics
1.14
-0.55
-32.54%
LTRN
Lantern Pharma
3.88
0.68
21.25%
CALC
CalciMedica
0.87
-0.83
-49.00%
Century Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Century Therapeutics Shareholders Approve Directors and Share Increase
Positive
Jun 12, 2026
Century Therapeutics held its Annual Meeting virtually on June 11, 2026, with 180,354,197 common shares eligible to vote as of the April 16, 2026 record date. Shareholders elected Alessandro Riva and Han Lee as Class II directors to serve until th...
Business Operations and StrategyProduct-Related Announcements
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy
Positive
Jun 8, 2026
Century Therapeutics reported new preclinical data on June 8, 2026, for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The data show...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Century Therapeutics Updates ATM Program to Enhance Liquidity
Positive
Mar 26, 2026
On July 10, 2025, Century Therapeutics, Inc. filed a new shelf registration statement that became effective on January 9, 2026, replacing its prior shelf registration and enabling continued access to the capital markets. In connection with this, o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.